Skip to main content

Table 3 Multivariate–adjusted hazard ratios for disease-free survival of lipocalin-2 and MMP-9

From: The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer

  No. of total patients ( N =303) No. of events ( N =87) Adjusted HRa (95% CI) P
Lipocalin-2 continuous    1.06 (1.02-1.09) 0.001
(ng/ml) t1 100 22 1.00 (reference)  
  t2 102 35 1.96 (1.12-3.43) 0.018
  t3 101 30 1.93 (1.07-3.47) 0.028
  P trend    1.36 (1.03-1.79) 0.029
MMP-9 continuous    1.02 (0.99-1.06) 0.136
(ng/ml) t1 100 22 1.00 (reference)  
  t2 102 34 1.95 (1.12-3.39) 0.018
  t3 101 31 1.70 (0.97-2.99) 0.065
  P trend    1.28 (0.99-1.67) 0.063
Combined scoreb low 101 24 1.00 (reference)  
  medium 100 28 1.55 (0.88-2.74) 0.130
  high 102 35 2.22 (1.29-3.84) 0.004
  P trend    1.49 (1.14-1.95) 0.004
  1. a Adjusted for BMI (< 25 and ≥25 kg/m2), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (yes and no).
  2. b The subjects were categorized into three groups based on the tertiles of combined score: low (1.092-3.463), medium (3.464-4.997) and high (4.998-14.276) score groups.